AstraZeneca live at ERS international congress 2016


We look forward to the 2016 European Respiratory Society International Congress as an important opportunity to advance respiratory science and care.

Recent developments in the understanding of respiratory disease pathways mean that we are entering an era of unprecedented potential to deliver scientific breakthroughs and transform the lives of people with asthma and COPD. Our 40-year heritage in respiratory science is just the beginning of our story. Hear more from the people at AstraZeneca behind our commitment to respiratory disease.


Latest from ERS 2016

Corporate press release





Our scientific focus: four pathways to the future

Gary Anderson Professor Gary Anderson, PhD, FThorSoc, FERS Chief Scientist, Respiratory, Inflammation and Autoimmune Innovative Medicines, AstraZeneca (on secondment from University of Melbourne, Australia)

We focus our respiratory research and development on four central ‘biological pathways’ that characterise chronic obstructive and autoimmune conditions and could provide a platform for disruptive breakthroughs in treatment.



Our respiratory pipeline

We have an exciting clinical pipeline in respiratory disease, underpinned by exceptional science.

35

Total compounds

125

Total indications

22

Progressed to the next phase


New approaches in the treatment of asthma

Targeting the immune system to try and restore the balance in asthma patients.

Read full story

Respiratory

Learn more about the work we do in the respiratory field.


Page Atlas ID: 1006480.011
Date of next review: August 2017